ArticleEJNMMI physics2026
Virtual-patient nonlinear mixed-effects modelling for data-driven optimisation of single-time-point dosimetry: a proof-of-concept study in [
Article in EJNMMI physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRobust single-time-point (STP) dosimetry critically depends on selecting an imaging time that yields reliable estimates of the time-integrated activity coefficient (TIAC). This study developed and evaluated a virtual-patient nonlinear mixed-effects modelling (NLMEM) framework to optimise STP imaging schedules for renal TIAC estimation, using [¹⁷⁷Lu]Lu-PSMA-617 therapy as a proof of concept.
methodsA previously published NLMEM (sum-of-exponentials structure and parameter distributions) describing renal [¹⁷⁷Lu]Lu-PSMA-617 biokinetics in 63 patients served as the generative model [1]. Based on fixed- and random-effects parameters, 500 virtual patients (VPs) were sampled, and reference TIAC values were computed analytically (rTIAC). For each candidate imaging time, renal activity measurements were simulated by applying proportional noise (7.9%). Estimated STP TIAC values (sTIAC) were obtained via leave-one-out cross-validation and compared with rTIAC to quantify population-level error metrics using mean absolute percentage error (MAPE) and root-mean-square error (RMSE). Time-dependent MAPE-time and RMSE-time profiles were modelled using polynomial fits selected by predefined goodness-of-fit criteria to identify time windows with low and stable errors. Individual-level robustness was assessed by quantifying extreme patient-specific relative deviations (RD) using thresholds of 10%, 20%, and 30%.
resultsMAPE- and RMSE-versus-time profiles were concordant and showed a pronounced minimum around 50 h post-injection. Among the investigated imaging time points, the lowest observed population-level error metrics occurred at 48 h, whereas polynomial modelling predicted an optimum centred at approximately 50 h (about 33-67 h). An additional VP-NLMEM evaluation at 50 h demonstrated comparable population-level performance and the lowest frequency of |RD| >30%, while the minima for the 10% and 20% thresholds occurred at nearby imaging times.
conclusionThe proposed virtual-patient NLMEM framework enables data-driven optimisation of STP imaging by identifying robust time windows that minimise both population-level error and extreme individual deviations in renal TIAC estimation for [¹⁷⁷Lu]Lu-PSMA-617 therapy. The approach appears transferable to STP dosimetry optimisation for other radiopharmaceuticals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.